Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study

Salvatore Rinaldi,1,2 Margherita Maioli,1,3,4 Sara Santaniello,3,4 Alessandro Castagna,1,2 Gianfranco Pigliaru,3,4 Sara Gualini,3,4 Matteo Lotti Margotti,5 Arturo Carta,6 Vania Fontani,1,2 Carlo Ventura1,4,71Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence; 2Department of Neu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rinaldi S, Maioli M, Santaniello S, Castagna A, Pigliaru GF, Gualini S, Margotti ML, Carta A, Fontani V, Ventura C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	ageing adipose derived stem cells neurodegenerative diseases Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/9b3e09700f3c4a22ab9c8eb57f50f2d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9b3e09700f3c4a22ab9c8eb57f50f2d8
record_format	dspace
spelling	oai:doaj.org-article:9b3e09700f3c4a22ab9c8eb57f50f2d82021-12-02T02:34:56ZRegenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study1178-1998https://doaj.org/article/9b3e09700f3c4a22ab9c8eb57f50f2d82012-06-01T00:00:00Zhttps://www.dovepress.com/regenerative-treatment-using-a-radioelectric-asymmetric-conveyor-as-a--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Salvatore Rinaldi,1,2 Margherita Maioli,1,3,4 Sara Santaniello,3,4 Alessandro Castagna,1,2 Gianfranco Pigliaru,3,4 Sara Gualini,3,4 Matteo Lotti Margotti,5 Arturo Carta,6 Vania Fontani,1,2 Carlo Ventura1,4,71Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence; 2Department of Neuro Psycho Physio Pathology and Neuro Psycho Physical Optimization, Rinaldi Fontani Institute, Florence; 3Department of Biomedical Sciences, University of Sassari, Sassari; 4Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems, Bologna; 5Department of Information Technology and Statistical Analysis, Rinaldi Fontani Institute, Florence; 6Ophthalmology Section, University of Parma, Parma; 7Cardiovascular Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, ItalyBackground: Beta-galactosidase is the most widely used biomarker for highlighting the processes of cellular aging, including neurodegeneration. On this basis, we decided to test in vitro whether a set of rescuing/reparative events previously observed by us in subjects treated with radioelectric asymmetric conveyor (REAC) technology may also involve antagonism of a marker of aging-related degenerative processes, as assessed by a reduction in beta-galactosidase at the cellular level.Methods: Human adipose-derived stem cells were cultured at different passages, ranging from 5 to 20, with or without REAC exposure for 12 hours. The cells were then processed for biochemical beta-galactosidase staining and morphological microscopy analysis.Results: We observed a significant reduction in expression of senescence associated-beta-galactosidase, and a persistence of fibroblast-like morphology typical of human adipose-derived stem cells, even at late passages.Conclusion: Our results indicate the ability of REAC technology to counteract in vitro senescence of human adipose-derived stem cells, and prompt the hypothesis that such technology may be exploited to antagonize in vivo senescence of tissue-resident or transplanted stem cells playing an important role in clinical treatment of age-related processes.Keywords: aging, adipose-derived stem cells, neurodegenerative diseasesRinaldi SMaioli MSantaniello SCastagna APigliaru GFGualini SMargotti MLCarta AFontani VVentura CDove Medical Pressarticleageingadipose derived stem cellsneurodegenerative diseasesGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 7, Pp 191-194 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	ageing adipose derived stem cells neurodegenerative diseases Geriatrics RC952-954.6
spellingShingle	ageing adipose derived stem cells neurodegenerative diseases Geriatrics RC952-954.6 Rinaldi S Maioli M Santaniello S Castagna A Pigliaru GF Gualini S Margotti ML Carta A Fontani V Ventura C Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
description	Salvatore Rinaldi,1,2 Margherita Maioli,1,3,4 Sara Santaniello,3,4 Alessandro Castagna,1,2 Gianfranco Pigliaru,3,4 Sara Gualini,3,4 Matteo Lotti Margotti,5 Arturo Carta,6 Vania Fontani,1,2 Carlo Ventura1,4,71Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence; 2Department of Neuro Psycho Physio Pathology and Neuro Psycho Physical Optimization, Rinaldi Fontani Institute, Florence; 3Department of Biomedical Sciences, University of Sassari, Sassari; 4Laboratory of Molecular Biology and Stem Cell Engineering, National Institute of Biostructures and Biosystems, Bologna; 5Department of Information Technology and Statistical Analysis, Rinaldi Fontani Institute, Florence; 6Ophthalmology Section, University of Parma, Parma; 7Cardiovascular Department, S Orsola Malpighi Hospital, University of Bologna, Bologna, ItalyBackground: Beta-galactosidase is the most widely used biomarker for highlighting the processes of cellular aging, including neurodegeneration. On this basis, we decided to test in vitro whether a set of rescuing/reparative events previously observed by us in subjects treated with radioelectric asymmetric conveyor (REAC) technology may also involve antagonism of a marker of aging-related degenerative processes, as assessed by a reduction in beta-galactosidase at the cellular level.Methods: Human adipose-derived stem cells were cultured at different passages, ranging from 5 to 20, with or without REAC exposure for 12 hours. The cells were then processed for biochemical beta-galactosidase staining and morphological microscopy analysis.Results: We observed a significant reduction in expression of senescence associated-beta-galactosidase, and a persistence of fibroblast-like morphology typical of human adipose-derived stem cells, even at late passages.Conclusion: Our results indicate the ability of REAC technology to counteract in vitro senescence of human adipose-derived stem cells, and prompt the hypothesis that such technology may be exploited to antagonize in vivo senescence of tissue-resident or transplanted stem cells playing an important role in clinical treatment of age-related processes.Keywords: aging, adipose-derived stem cells, neurodegenerative diseases
format	article
author	Rinaldi S Maioli M Santaniello S Castagna A Pigliaru GF Gualini S Margotti ML Carta A Fontani V Ventura C
author_facet	Rinaldi S Maioli M Santaniello S Castagna A Pigliaru GF Gualini S Margotti ML Carta A Fontani V Ventura C
author_sort	Rinaldi S
title	Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
title_short	Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
title_full	Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
title_fullStr	Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
title_full_unstemmed	Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
title_sort	regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/9b3e09700f3c4a22ab9c8eb57f50f2d8
work_keys_str_mv	AT rinaldis regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT maiolim regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT santaniellos regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT castagnaa regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT pigliarugf regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT gualinis regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT margottiml regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT cartaa regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT fontaniv regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy AT venturac regenerativetreatmentusingaradioelectricasymmetricconveyorasanoveltoolinantiagingmedicineaninvitrobetagalactosidasestudy
_version_	1718402364345417728

Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study

Ejemplares similares